170 related articles for article (PubMed ID: 1329989)
1. Structural features of the antibody-A chain linkage that influence the activity and stability of ricin A chain immunotoxins.
Cumber AJ; Westwood JH; Henry RV; Parnell GD; Coles BF; Wawrzynczak EJ
Bioconjug Chem; 1992; 3(5):397-401. PubMed ID: 1329989
[TBL] [Abstract][Full Text] [Related]
2. Stability and cytotoxicity of Fab-ricin A immunotoxins prepared with water soluble long chain heterobifunctional crosslinking agents.
Woo BH; Lee JT; Park MO; Lee KR; Han JW; Park ES; Yoo SD; Lee KC
Arch Pharm Res; 1999 Oct; 22(5):459-63. PubMed ID: 10549572
[TBL] [Abstract][Full Text] [Related]
3. New coupling agents for the synthesis of immunotoxins containing a hindered disulfide bond with improved stability in vivo.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Knyba RE; Wawrzynczak EJ; Blakey DC
Cancer Res; 1987 Nov; 47(22):5924-31. PubMed ID: 3499221
[TBL] [Abstract][Full Text] [Related]
4. Enhanced stability in vitro and in vivo of immunoconjugates prepared with 5-methyl-2-iminothiolane.
Carroll SF; Bernhard SL; Goff DA; Bauer RJ; Leach W; Kung AH
Bioconjug Chem; 1994; 5(3):248-56. PubMed ID: 7918744
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics in the rat of a panel of immunotoxins made with abrin A chain, ricin A chain, gelonin, and momordin.
Wawrzynczak EJ; Cumber AJ; Henry RV; May J; Newell DR; Parnell GD; Worrell NR; Forrester JA
Cancer Res; 1990 Dec; 50(23):7519-26. PubMed ID: 2253201
[TBL] [Abstract][Full Text] [Related]
6. Comparative biochemical, cytotoxic and pharmacokinetic properties of immunotoxins made with native ricin A chain, ricin A1 chain and recombinant ricin A chain.
Wawrzynczak EJ; Cumber AJ; Henry RV; Parnell GD
Int J Cancer; 1991 Jan; 47(1):130-5. PubMed ID: 1985869
[TBL] [Abstract][Full Text] [Related]
7. Role of cross-linking agents in determining the biochemical and pharmacokinetic properties of Mgr6-clavin immunotoxins.
Dosio F; Arpicco S; Adobati E; Canevari S; Brusa P; De Santis R; Parente D; Pignanelli P; Negri DR; Colnaghi MI; Cattel L
Bioconjug Chem; 1998; 9(3):372-81. PubMed ID: 9576812
[TBL] [Abstract][Full Text] [Related]
8. Improved antitumor effects of immunotoxins prepared with deglycosylated ricin A-chain and hindered disulfide linkages.
Thorpe PE; Wallace PM; Knowles PP; Relf MG; Brown AN; Watson GJ; Blakey DC; Newell DR
Cancer Res; 1988 Nov; 48(22):6396-403. PubMed ID: 3263186
[TBL] [Abstract][Full Text] [Related]
9. Recombinant ricin A chain conjugated to monoclonal antibodies: improved tumor cell inhibition in the presence of lysosomotropic compounds.
Ramakrishnan S; Bjorn MJ; Houston LL
Cancer Res; 1989 Feb; 49(3):613-7. PubMed ID: 2783383
[TBL] [Abstract][Full Text] [Related]
10. Thiol-containing cross-linking agent with enhanced steric hindrance.
Greenfield L; Bloch W; Moreland M
Bioconjug Chem; 1990; 1(6):400-10. PubMed ID: 2129154
[TBL] [Abstract][Full Text] [Related]
11. The effect of ricin B chain on the intracellular trafficking of an A chain immunotoxin.
Timar J; McIntosh DP; Henry R; Cumber AJ; Parnell GD; Davies AJ
Br J Cancer; 1991 Oct; 64(4):655-62. PubMed ID: 1911213
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies.
Ramakrishnan S; Houston LL
Cancer Res; 1984 Jan; 44(1):201-8. PubMed ID: 6140077
[TBL] [Abstract][Full Text] [Related]
13. Laboratory preparation of a deglycosylated ricin toxin A chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies.
Vallera DA; Burns LJ; Frankel AE; Sicheneder AR; Gunther R; Gajl-Peczalska K; Pennell CA; Kersey JH
J Immunol Methods; 1996 Oct; 197(1-2):69-83. PubMed ID: 8890895
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic effects of ricin without an interchain disulfide bond: genetic modification and chemical crosslinking studies.
Mohanraj D; Ramakrishnan S
Biochim Biophys Acta; 1995 Apr; 1243(3):399-406. PubMed ID: 7727515
[TBL] [Abstract][Full Text] [Related]
15. Comparison of two anti-Thy 1.1-abrin A-chain immunotoxins prepared with different cross-linking agents: antitumor effects, in vivo fate, and tumor cell mutants.
Thorpe PE; Blakey DC; Brown AN; Knowles PP; Knyba RE; Wallace PM; Watson GJ; Wawrzynczak EJ
J Natl Cancer Inst; 1987 Nov; 79(5):1101-12. PubMed ID: 2890786
[TBL] [Abstract][Full Text] [Related]
16. Blocked and non-blocked ricin immunotoxins against the CD4 antigen exhibit higher cytotoxic potency than a ricin A chain immunotoxin potentiated with ricin B chain or with a ricin B chain immunotoxin.
Wawrzynczak EJ; Watson GJ; Cumber AJ; Henry RV; Parnell GD; Rieber EP; Thorpe PE
Cancer Immunol Immunother; 1991; 32(5):289-95. PubMed ID: 1998970
[TBL] [Abstract][Full Text] [Related]
17. Enhanced stability of an immunotoxin made with abrin A chain and a hindered disulphide cross-linker.
Cumber A; Wawrzynczak E
Biochem Soc Trans; 1992 Nov; 20(4):312S. PubMed ID: 1486982
[No Abstract] [Full Text] [Related]
18. Generation and characterization of an anti-CD19 single-chain Fv immunotoxin composed of C-terminal disulfide-linked dgRTA.
Wang D; Li Q; Hudson W; Berven E; Uckun F; Kersey JH
Bioconjug Chem; 1997; 8(6):878-84. PubMed ID: 9404661
[TBL] [Abstract][Full Text] [Related]
19. Biochemical, cytotoxic and pharmacokinetic properties of an immunotoxin composed of a mouse monoclonal antibody Fib75 and the ribosome-inactivating protein alpha-sarcin from Aspergillus giganteus.
Wawrzynczak EJ; Henry RV; Cumber AJ; Parnell GD; Derbyshire EJ; Ulbrich N
Eur J Biochem; 1991 Feb; 196(1):203-9. PubMed ID: 2001699
[TBL] [Abstract][Full Text] [Related]
20. Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity.
Pietersz GA; Kanellos J; McKenzie IF
Cancer Res; 1988 Aug; 48(16):4469-76. PubMed ID: 3260814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
